Len. you, Thank
talk nonstop throughout unfortunately, lot working been And who morning, pandemic. in the world possible Regeneron still this global is to COVID-XX this a of have all pandemic. colleagues about of the is have which throes our this We because
climbing EUA, individuals Use I risk to subcutaneous death the data of the monoclonal was dose In United nearly updated in start infected that was infected gram include for number Americans intravenous As becoming Authorization, again by day. for antibody III This June, XXX,XXX our the REGEN-COV patients. will and X.X REGEN-COV, administration XX%. or hospitalization EUA States Phase the with Emergency dose gram showing or both cocktail X.X are with reduce the with COVID-XX. of Therefore, Regeneron lower nonhospitalized supported by every with REGEN-COV
the are and treatment settings. Still REGEN-COV which infected like for REGEN-COV FDA include we pre-exposure could treatment of has high among is The hospitalized to only substitute in of is New III also and that prophylaxis both in the post-exposure efficacy paradigm the for Phase monthly not to is unmet the subcutaneous Part high-risk preventing review was A certain and prophylaxis REGEN-COV EUA prophylaxis the try to individuals for individuals that populations, by patients. previously in of individuals prevention hope setting. of protect risk in This assessed FDA certain that makes last for at for to the vaccine details data we who patients, latest available will application COVID-XX to preventing Medicine. as We Just under would and pre-exposure to prophylaxis our ongoing England have in uninfected exposure utilization as vaccination. extend an this believe week, in enormous setting. We been a responded in we that just immunocompromised authorization safety broaden the immunocomprised there same agree in expanded our infection Journal authorization allows which treating repeated of today as data, to well the the need infected support also believe of further study institutional individuals published such infection to the are who not to dosing will emphasize REGEN-COV additional
as hospitalized patients, primary lacking COVID-XX mortality met to III limited hospitalized of with Phase oxygen with hospitalized from recovery support. recently RECOVERY Data response in University patients study and risk death reducing was reported have by immune REGEN-COV no conclusions been own patients from in from Oxford showed of For the data tested smaller part in XX% our overall study we hospitalized its outcome, our study SARS-CoV-X. study, shared collective COVID-XX regulators. this similar oxygen These with earlier-stage patients which hospitalized in low patients or to reduction XX% that in
half on complete pandemic addition, REGEN-COV the of our XXXX. track in was India, Union, In XX we obtained for collaborator States, with the cocktail, or temporary for known second Ronapreve soon. to cocktail regulatory Roche as COVID-XX. across Canada, outside the Japan States expected of more our antibody Outside COVID-XX formal our country European the use United are than BLA authorizations emergency submissions more approval the countries United Switzerland and to grant authorizations in the antibody first to
Finally, known retains against Delta potent interest, REGEN-COV including activity the of variants variant. all
consequences, high foreseeable serious the response For could physicians future. patients risk at their vaccines, an important including patients option many to inadequate be to with of REGEN-COV for an and
Moving have the months, will In in dose as This II of study high approved expect wet open-label other libracept dosing coming on from dosed II libracept anatomical AMD. dose patients and X-milligram drawing date, as of X-milligram the concerning in we to an currently of signals. we measures not consist seen ophthalmology. on safety safety any interval. efficacy the and readout In assessments of the well the in X-week to data Phase Phase on XXX the
studies be Phase Phase high-dose III II to intervals measures, pleased DME the enrollment, next data the XX not allowing completed into smaller study announce help out will While AMD III and Phase the year. XX are the have definitive insights that studies, provide weeks. Phase to I'm durability larger aflibercept will for dosing which on III and data in testing
to inflammation our on portfolio. in and immunology Moving Dupixent
in and from approved inflammatory diseases. as readout and in showing as XX well CSU, announced In across in of this adolescent disease X week, in in this Dupixent last possibility chronic in XX-week as we the IIIb children in regulatory United Dupixent urticaria, months nodularis. endpoints, as of traditionally in Dupixent to continuing met are X key results in suffering are Phase prurigo preschool States. IL-XX activity results months, old trial old demonstrated atopic scores build patients patients readout to CSU to study confirmatory be adult patients and also which trial Dupixent's in disease nearly atopic trial from fifth Later Phase esophagitis and children October early sought years from This data IL-X the who second years efficacy from the biologic not We upcoming demonstrated anticipate age III XX decision a study primary hive of type Phase safety raises aged positive all This we in plan Thus spontaneous dermatitis itch as care on in in X far, the asthma, is and a secondary in results a is Phase by our the asthma. and in where report is young and expect CSU benefiting from Just diseases dermatitis. and years eosinophilic up to that young other drivers pivotal X half. reduced by positive of standard study a we years with approved report efficacy we XXXX. not will critical for X to inflammation. In year, driven a as old III III
population. reduction our what population, of patients the benefit on analyses the Moreover, not and former primary lung Results trends reaching in with liters compared overall prespecified XX% in prespecified Itupikumab. were in X.XX subset in reduction overall on includes Moving smoker Lancet its endpoints genetic placebo Sanofi study endpoint improvement recently the Respiratory Phase in results, that to for Itupikumab subgroup COPD COPD COPD. face exhibited meet which II studies both role no in in two the interleukin-XX All In potential nominal studies interleukin-XX significance, negative statistical statistical the published demonstrated a are two population the the with a also complementary III of with have we III in remaining Dupixent and trial a Itupikumab smoker did exacerbation studies with COPD. I you accounted we focus strong of subgroup, support of to the a protective assessing publication these in Medicine. is COPD significance. exacerbations two of for analysis function the former smokers anti remind former ongoing -- population. Based with we ongoing that Phase in should antibody Phase
studies. which antibody We caused of by bind allergen and allergies expected allergens, are directly III the approaches Phase this II the have to novel also virtue results of progressing to against in year. produced Phase cocktail inactivate robust antibodies cocktails our study are our treat BetvX using initial monoclonal of by later allergy Results
cat The first now enrollment. is antibody cocktail Phase allergy FeldX an III caused allergen, by for study of open the for
We enthusiastic United oncology, additions innovative its compelling or Libtayo FDA approved second-line with ESMO the cervical were and survival these lung overall virtual in to planned immunology certain States in this planar cell regulatory the inflammation Furthermore, following certain cancer was are in presented May EMA about for for at EU these data year. portfolio. settings. in our submissions the subsequently the patients an approvals In to carcinoma first-line advanced basal cell and patients, recent cancer in non-small
lung second efficacy Libtayo overall plus non-small today locally For or versus in the for lung analysis. chemotherapy comparing committee Tylus chemotherapy standard first-line significantly III at Phase the cell metastatic cancer. in advanced monitoring trial pleased that the improved survival report independent alone cancer, alone well recommended to trial progression-free compared interim surveil our chemotherapy to chemotherapy we with as halting as data are
in that With as both overall well the has validation, treating for need face. and for significant and in particular, Libtayo important approach monotherapy these benefit a as with second able cancer. chemotherapy lung cancer, as broad advanced a in to Libtayo demonstrate patients antibody to still is this data, With an now targeting general provides PD-X the foundation with great lung cancer combination address survival unmet been that multifaceted
chemo are In monotherapy and Libtayo addition cancer, developing to lung in our combination opportunities bispecifics. we several
in combination other for lung Our escalation cancers. EGFR by is and and Libtayo CDXX costim dose advanced
MET investor including METxMET ADC, event, selection is enter exon patients cell lung the antibody in with MET Our patients. XX% antibody clinic our cancers, expression. of on conjugate introduced first cancer, broad patients, MET at focus the where gene with we occurs lung with mutation, as as patients METxMET drug bispecific months coming elevated And including amplification poised gene expression is ASCO as protein a enrolling cancer in XX overexpressing to a over many net non-small and/or our
than Tyle inhibitor, June. response annual ASCO In terms a testing at potential of Fianlimab with announced the for demonstrated of advanced clinical our potential with PD-X melanoma initiate or with for of in three anti-CTLA-X approaches. combinations. to with treatment PDL-X new building Tylus combination XXXX. the a more is as we plan III PD-X are study the in skin cancer, clinically in LAG-X tumor favorable melanoma cancer which recently advanced Libtayo Fianlimab rate combinations on for in Ovarian XX% safety combination in first-line for type naive powerful first Phase The the data patients a meeting profile and combinant We a we
First, next where data MUCXXxCDX to our initial with bispecific share we Libtayo, year. hope
third, tumors. for first be share of tumors, And in CDX This a next costim potential our classes treatment cancer we solid which we with and and PSMAxCDXX continues the approach novel program in Rounding in data dose of to patient. novel have the bispecifics two for my hope out combination and with now Libtayo, escalation year. costim combination prostate bispecific bispecifics MUCXXxCDXX initial different disruptive of solid has two Libtayo. to dosed our our the latter Next, of commentary
nonresponsive are another viewed planning available immunotherapies. introducing this currently experimental on clinic tumor prostate for to As later treatment. we The mentioned combination previously, we cancer to bispecific year, PSMAxCDX unique a the providing as
encouraging hematologic lymphoma. has on our in bispecific to Moving patient responses with durability efficacy hard-to-treat and starting of emulations. Odronextamab, cancers demonstrated and CDXX
this with bispecific. BCMAxCDX as formulation. as pivotal complete pivotal diffuse we a lymphoma our Phase costim track potentially initiate protocol to year. to II hold and in exome well plan And is step-up program enrollment next the In the lymphoma-specific large multiple follicular study our lifting subcutaneous combination lymphoma, resumed bispecific the to year, in for B-cell program trials III on II of myeloma, Later with next enrollment partial have testing we dosing potentially modified clinical of Phase plan We following amendments year, initiate protocol. Phase our
With with with observing Medicines Genetic our subcutaneous multiple and year. initiate start BCMAxCDX standard our to to are like targets a will track already match of studies are and We goal position multiple the the conclude formulation modalities care. also we costim bispecific evaluating to our efforts. a with combinations mix with responses we unique bispecific study on would of in with for a next combination Regeneron I myeloma deepening
validate is ability well collaborator with are our gene-based genetically Alnylam developing technologies to efforts you in that with our and Most human solutions genetic targets, a new high-profile a either technologies Genetics can described target these technologies its siRNA variants identifying Regeneron in in leader as to debility world human Center with Science therapeutic major causative last disease. and start disease be these in-house. we that with as As protects The emerge recently new Regeneron gene including as continues identify viral for address protective emerging know, to sequencing targets Genetics Center coupled CRISPR-based or Intellia, publication defining in obesity and month. as a against and gene
type discovered to strategies develop deploying are potential two this fight therapeutics diabetes. several to of For classes and new we newly target, potentially obesity
adverse unlocking serious positive systemic the in first with the of a to single gene the terms of for for possibilities Intellia our the knockout protein In well events than as future and reduction the the potential under of of and success patients. our dose-dependent many therapeutic amyloidosis gene-based with collaboration, first approaches, programs, data Intellia, In amyloidosis, both Currently, TTR proof CRISPR-based to probability up in to clinical more develop with we ever our preclinical XX. led progress increases knockout data observed together with with Regeneron. through patients announced products XX treatment delivered Intellia. X has insertion recently as we're clinical with systemically evaluating rights no CRISPR-based for human transthyretin the day vivo disease-causing this XX Regeneron programs This asset in
efforts on volunteer the by to Regarding novel initial This siRNA year. this with study by Center, for of the enrolling are NASH we now target Genetic an patients. NASH see healthy end our data Regeneron hoping is a Alnylam, first-in-human X-part identified
collaboration XX glimpse with this to about like evaluating turn into develop and I brief With Marion. that to Alnylam. XX would has to programs to future under currently are up genetic We the preclinical rights over products Regeneron the of call medicines,
